TABLE 3.
Lack of effect of MR-1 treatment on sepsis and lung infections in BALB/cByJ mice following i.t. inoculation of BG9163 pneumococci
| Treatmenta | Day of assay | n | Mean log10 CFU/lung ± SE in:
|
Mean log10 CFU/ml of blood | ||
|---|---|---|---|---|---|---|
| Right lung | Left lung | Both lungs | ||||
| MR-1 | 1 | 6 | 3.0 ± 0.1 | 2.8 ± 0.6 | 3.5 ± 0.3 | 2.7 ± 0.6 |
| Hamster IgG | 1 | 6 | 3.7 ± 0.9 | 3.8 ± 0.8 | 4.2 ± 0.7 | 3.6 ± 0.8 |
| MR-1 | 3 | 6 | 1.6 ± 0.3 | 1.4 ± 0.4 | 1.8 ± 0.4 | 2.9 ± 0.4 |
| Hamster IgG | 3 | 6 | 3.2 ± 0.9 | 2.5 ± 1.0 | 3.3 ± 0.9 | 3.3 ± 0.9 |
a
MR-1 protocol: mice were inoculated with BG9163 on day 0 and treated with 250 μg of MR-1 on days −1, +1, and 2. No MR-1 values differed from hamster IgG at P < 0.05 for any of the individual comparisons by the Wilcoxon rank sum test.